

DFU



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Noble et al.

Examiner: Unknown

Serial No.: 10/563,077

Group Art Unit: 1639

Filed: December 29, 2005

Docket: UCLA.0154USWO

Title: GENETIC MARKER OF RESPONSE TO ATYPICAL ANTIPSYCHOTICS AND ANTIDEPRESSANTS AND METHODS FOR USE THEREOF

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 22313-1450 on November 6, 2006.

By: _____

Name: Karen S. Canady

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate Of Mailing or Transmission Under 37 CFR 1.8.
- ☒ Request for Corrected Filing Receipt
- ☒ Photocopy of the Filing Receipt showing the requested changes
- ☒ Return postcard.

Customer Number 59612

Canady & Lortz

11340 W. Olympic Blvd, Suite 275
Los Angeles, California 90064
(310) 966-9400
Fax: (909) 494-4441

By: _____

Name: Karen S. Canady

Reg. No.: 39927

Date: November 6, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Noble et al.

Examiner: Unknown

Serial No.: 10/563,077

Group Art Unit: 1639


Filed: December 29, 2005

Docket: UCLA.0154USWO

Title: GENETIC MARKER OF RESPONSE TO ATYPICAL ANTIPSYCHOTICS AND ANTIDEPRESSANTS AND METHODS FOR USE THEREOF

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 22313-1450 on November 6, 2006.

By: 
Name: Karen S. Canady

REQUEST FOR CORRECTED FILING RECEIPT

Attn: Office of Initial Patent Examination
Customer Service Center
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a photocopy of the filing receipt from the U.S. Patent and Trademark Office in the above-identified application showing requested corrections. The filing receipt is erroneous in the following respects as reflected in the papers originally filed on December 29, 2005.

The requested corrections are shown in **Bold** as follows:

Title: Genetic marker of response to atypical antipsychotics and antidepressants **and** methods for use thereof

Inventor #2: **Ross** M. Young, Queensland, AUSTRALIA

Correction of the records of the U.S. Patent and Trademark Office and issuance of a corrected filing receipt are respectfully solicited.


Respectfully submitted,

Canady & Lortz LLP
11340 W. Olympic Blvd, Suite 275
Los Angeles, California 90064
(310) 966-9400
Fax: (909) 494-4441

By: 

Name: Karen S. Canady
Reg. No.: 39,927

Date: 11-6-06



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/563,077	12/29/2005	1639	300	UCLA.154USWO	5	4	1

CONFIRMATION NO. 3519

59612
 KAREN S. CANADY
 CANADY & LORTZ LLP
 COMMERCE PLAZA
 11340 WEST OLYMPIC BLVD., SUITE 275
 LOS ANGELES, CA 90064

FILING RECEIPT



OC000000020925671

Date Mailed: 10/23/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

ROSS → Ernest P. Noble, Laguna Beach, CA;
 Rose M. Young, Queensland, AUSTRALIA;
 Bruce R. Lawford, Queensland, AUSTRALIA;

Power of Attorney: The patent practitioners associated with Customer Number **22462**.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/22064 07/08/2004
 which claims benefit of 60/485,482 07/08/2003

Foreign Applications

If Required, Foreign Filing License Granted: 10/20/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/563,077**

Projected Publication Date: 02/01/2007

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

RECEIVED

OCT 30 2006

canady + lortz

Title

and

Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.